ROSEMOUNT
SpecialtyROSEMOUNT is a specialty pharmaceutical company focused on Neurology, Cardiovascular. Key products include OZOBAX DS.
ROSEMOUNT's Key Drugs
ROSEMOUNT's core commercial portfolio centers on OZOBAX DS, spanning Neurology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
ROSEMOUNT's Recent FDA Approvals
New NDA/BLA approvals for ROSEMOUNT over the last two years — novel drugs only, excluding generics and label supplements.
ROSEMOUNT's Therapeutic Areas
ROSEMOUNT's approved drugs and pipeline span 2 therapeutic areas, led by Neurology and Cardiovascular, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ROSEMOUNT's Top Competitors
ROSEMOUNT's closest competitors by therapeutic-area and drug-target overlap include GE HEALTHCARE, Novo Nordisk, and AZURITY. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ROSEMOUNT Pipeline Snapshot
Active clinical trials for ROSEMOUNT across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • OZOBAX DS leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling